AlphAIAlphAI — Financial news for AI agents
theglobeandmail.comOCT 101 min read$INCY

Incyte (INCY) Receives a Buy from Bank of America Securities

Bank of America Securities reiterated a Buy rating on Incyte (INCY) with a $140 price target. H.C. Wainwright also gave a Buy, while RBC Capital maintained a Hold. Incyte reported Q2 revenue of $1.67B and net profit of $585.61M, up from $1.22B and $405M last year. Insider sentiment is negative, with recent sales by executives.

Original reporting
theglobeandmail.com
Published Oct 10, 2026, 12:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 10, 2026, 1:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Incyte (INCY) Receives a Buy from Bank of America Securities — source image
Source · theglobeandmail.com
Decision brief

The 30-second read

$INCYBullishLow
01

Why it matters

The Buy rating and $140 target could prompt short-term buying pressure, but insider sales and modest earnings growth temper expectations.

02

Market read

Limited relevance; primarily an analyst opinion without new corporate data.

03

What to watch

Insider selling activity could offset the positive analyst view.

Relevance 4/10Novelty 2/10Timing: today

Background

The article reports an analyst rating reiteration and recent earnings figures for Incyte.

Company-level read

Ticker impact

$INCYBullishMedium confidence
Context

Bank of America Securities reiterated a Buy rating on Incyte and set a $140 price target.

Expected impact

likely slight upside as investors price in the higher target.

Evidence & confidence

Buy rating and $140 target are new analyst opinions, but no fresh company fundamentals were disclosed.

Market effects

Sector

Minimal impact on the broader healthcare sector.

Regional

Limited to U.S. investors tracking biotech stocks.

Global

Low

Counterpoint

What could challenge this read

The rating may be premature given modest earnings growth.

Key entities

  • company
    Incyte

    Biopharmaceutical company (NASDAQ: INCY).

  • analyst
    Bank of America Securities

    Equity research firm issuing the Buy rating.

Read at source← All news

Related articles

OCT 13
Med

HC Wainwright & Co. reiterates Buy rating on Incyte, $152 price target

HC Wainwright & Co. reiterated a Buy rating on Incyte (INCY) with a $152 price target, suggesting a 36.5% upside from the Oct 12 close. The firm cited strong pipeline potential, particularly for drug INCB161734, with a 69% response rate in untreated patients and projected annual sales of $700 million in the U.S. G12D pancreatic cancer market.

tradingview.com1 min
OCT 13
$SNDXHighAI 8/10

Syndax shares fall as lung fibrosis drug fails trial

Syndax Pharma's shares fell 17% pre-market after abandoning its IPF drug axatilimab, which failed a phase 2 trial. The drug, partnered with Incyte, is approved for cGVHD as Niktimvo. Incyte's shares also dipped slightly. Syndax reported $152M in 2025 revenue, with $115M in the first half of 2026.

pharmaphorum.com2 min
OCT 7
$INCYMed

Incyte (INCY) Won New Approvals, Is The Pullback A Cheap Entry?

Incyte (INCY) received U.S. approval for Atebrioz and Brazil's expedited approval for NIKTIMVO. Shares are down 6.52% in 7 days and 10.50% in 30 days, but up 11.85% year-to-date and 32.86% in 1 year. The stock trades 14% below the average analyst price target. Incyte's 2026 guidance projects total net sales of $5.13B-$5.26B and Opzelura net sales of $1.05B-$1.10B. Analysts value the stock at $128.48, while a DCF model values it at $93.58.

simplywall.st2 min